CoTherix Report issue

Contributed to NME For profit Phase 2
Founded: San Francisco CA United States (2000)
Status: Acquired by Actelion (2006) → now Johnson and Johnson (2017)

Organization Overview

First Clinical Trial
2004
NCT00086463
First Marketed Drug
2004
iloprost (ventavis)
First NDA Approval
2004
iloprost (ventavis)
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

iloprost (ventavis) (2004 NDA)

Drugs in Phase 2 Trials (1)

iloprost (ventavis) (2 trials)

Indications

Approved Indications


 

Hypertension, Pulmonary

Experimental Indications (Clinical Trials, Phases 1-4)


 

Familial Primary Pulmonary Hypertension (Phase 2)

Fibrosis (Phase 2)

Hypertension (Phase 2)

Hypertension, Pulmonary (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1